Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) signed asset acquisition agreement to acquire the remaining 80.95% stake in Chongqing Laimei Heyuan Investment Co Ltd from Shanghai Dingliang Heyuan Investment Center (Limited Partnership), Shanghai Liuhe Yuankui Investment Center (Limited Partnership) and 12 individuals for CNY 340 million in cash and stock on May 2, 2013. Chongqing Lummy will acquire 73.33% stake from Shanghai Dingliang Heyuan, Shanghai Liuhe Yuankui, Qiu Yu, Liu Wei, Wang Ruoyue, Li Ke, Zhou Heping, Wang Xu, Hu Yongxiang, Gang Shuang, Dai Qingping, Zhang Kaifei and Cui Dan and 7.62% stake from Qiu Wei. As a part of consideration, Chongqing Lummy will issue 14.41 million shares for acquisition of 73.33% stake in Laimei Heyuan and will pay CNY 31.95 million in cash for 7.62% stake. Chongqing Lummy will issue 2.81 million shares to Shanghai Dingliang Heyuan, 1.4 million shares to Shanghai Liuhe Yuankui, 9.97 million shares to Qiu Yu, 0.03 million shares each to Wang Ruoyue and Li Ke, 0.02 million shares each to Zhou Heping, Wang Xu, Hu Yongxiang, Gang Shuang, Zhang Kaifei and Dai Qingping, 4679 shares to Cui Dan. The cash consideration of CNY 31.95 million is to be paid within 10 working days after the completion of the registration modification for industry and commerce of Chongqing Laimei Heyuan is completed. Chongqing Lummy Pharmaceutical will issue up to 5.73 million new shares via a private placement to collect CNY 110 million to fund the acquisition.

On April 27, 2013, Shanghai Dingliang Heyuan and Shanghai Liuhe Yuankui approved the transfer of stake in Chongqing Laimei Heyuan. The transaction was approved by shareholders of Laimei Heyuan on May 2, 2013. The transaction was approved by Board of Directors of Chongqing Lummy on June 1, 2013 and was approved by shareholders of Chongqing Lummy on June 21, 2013. As of August 2, 2013, the transaction was authorized by China Securities Regulatory Commission. Sichuan Hua Xin (Group) CPA Firm acted as accountant, Sinolink Securities Co., Ltd. and Tianfeng Securities Brokerage Co., Ltd. acted as financial advisor and Zhong Lun Law Firm acted as legal advisor for Chongqing Lummy Pharmaceutical.

Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) completed the acquisition of 80.95% stake in Chongqing Laimei Heyuan Investment Co Ltd from Shanghai Dingliang Heyuan Investment Center (Limited Partnership), Shanghai Liuhe Yuankui Investment Center (Limited Partnership) and 12 individuals on September 5, 2013.